Short report

Temozolomide and cisplatin in relapsed/refractory acute leukemia

Karen Seiter , Sreedhar Katragadda , Doris Ponce , Muhammad Rasul and Nasir Ahmed

Department of Medicine, New York Medical College, Valhalla, New York 10595, USA

author email corresponding author email

Journal of Hematology & Oncology 2009, 2:21doi:10.1186/1756-8722-2-21

Published:	22 May 2009

Abstract

Cisplatin depletes MGMT and increases the sensitivity of leukemia cells to temozolomide. We performed a phase I study of cisplatin and temozolomide in patients with relapsed and refractory acute leukemia. Fifteen patients had AML, 3 had ALL, and 2 had biphenotypic leukemia. The median number of prior chemotherapy regimens was 3 (1–5). Treatment was well tolerated up to the maximal doses of temozolomide 200 mg/m²/d times 7 days and cisplatin 100 mg/m² on day 1. There was one complete remission in this heavily pretreated patient population. Five of 20 (25%) patients demonstrated a significant reduction in bone marrow blasts.